These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35750354)

  • 21. A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Gold MA; Brady WE; Lankes HA; Rose PG; Kelley JL; De Geest K; Crispens MA; Resnick KE; Howell SB
    Gynecol Oncol; 2012 Jun; 125(3):635-9. PubMed ID: 22446624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
    Coleman RL; Duska LR; Ramirez PT; Heymach JV; Kamat AA; Modesitt SC; Schmeler KM; Iyer RB; Garcia ME; Miller DL; Jackson EF; Ng CS; Kundra V; Jaffe R; Sood AK
    Lancet Oncol; 2011 Nov; 12(12):1109-17. PubMed ID: 21992853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statistical analysis plan for the Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type, and carcinosarcoma) trial (DICE).
    de la Rosa CN; Krell J; Day E; Clarke A; Reddi M; Webber L; Fiorentino F
    Trials; 2022 Jan; 23(1):13. PubMed ID: 34986897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
    Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 1 Study of Low-Dose Fractionated Whole Abdominal Radiation Therapy in Combination With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer (GCGS-01).
    Ngoi NYL; Heong V; Tang JI; Choo BA; Kumarakulasinghe NB; Lim D; Low M; Lim SE; Lim YW; Leong YH; Tseng M; Tong PSY; Ilancheran A; Low JJH; Ng J; Thian YL; Koh V; Tan DSP
    Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):701-711. PubMed ID: 33045316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial.
    Lee JY; Kim BG; Kim JW; Lee JB; Park E; Joung JG; Kim S; Choi CH; Kim HS;
    J Gynecol Oncol; 2022 Jul; 33(4):e45. PubMed ID: 35320892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.
    Grisham RN; Moore KN; Gordon MS; Harb W; Cody G; Halpenny DF; Makker V; Aghajanian CA
    Clin Cancer Res; 2018 Nov; 24(22):5525-5533. PubMed ID: 29844129
    [No Abstract]   [Full Text] [Related]  

  • 29. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.
    Ten Bokkel Huinink WW; Sufliarsky J; Smit WM; Spanik S; Wagnerova M; Hirte HW; Kaye S; Johri AR; Oza AM
    J Clin Oncol; 2009 Jul; 27(19):3097-103. PubMed ID: 19451434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
    Cheng M; Lee HH; Chang WH; Lee NR; Huang HY; Chen YJ; Horng HC; Lee WL; Wang PH
    Int J Environ Res Public Health; 2019 Nov; 16(23):. PubMed ID: 31795359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.
    McNeish IA; Ledermann JA; Webber L; James L; Kaye SB; Hall M; Hall G; Clamp A; Earl H; Banerjee S; Kristeleit R; Raja F; Feeney A; Lawrence C; Dawson-Athey L; Persic M; Khan I
    Ann Oncol; 2014 Oct; 25(10):1988-1995. PubMed ID: 25070546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
    Pignata S; Lorusso D; Scambia G; Sambataro D; Tamberi S; Cinieri S; Mosconi AM; Orditura M; Brandes AA; Arcangeli V; Panici PB; Pisano C; Cecere SC; Di Napoli M; Raspagliesi F; Maltese G; Salutari V; Ricci C; Daniele G; Piccirillo MC; Di Maio M; Gallo C; Perrone F;
    Lancet Oncol; 2015 May; 16(5):561-8. PubMed ID: 25882986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.
    Markman M; Hall J; Spitz D; Weiner S; Carson L; Van Le L; Baker M
    J Clin Oncol; 2002 May; 20(9):2365-9. PubMed ID: 11981009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study.
    Moore KN; Chambers SK; Hamilton EP; Chen LM; Oza AM; Ghamande SA; Konecny GE; Plaxe SC; Spitz DL; Geenen JJJ; Troso-Sandoval TA; Cragun JM; Rodrigo Imedio E; Kumar S; Mugundu GM; Lai Z; Chmielecki J; Jones SF; Spigel DR; Cadoo KA
    Clin Cancer Res; 2022 Jan; 28(1):36-44. PubMed ID: 34645648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
    Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
    Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Matulonis UA; Sill MW; Makker V; Mutch DG; Carlson JW; Darus CJ; Mannel RS; Bender DP; Crane EK; Aghajanian C
    Gynecol Oncol; 2019 Mar; 152(3):548-553. PubMed ID: 30587441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.
    Blagden SP; Hamilton AL; Mileshkin L; Wong S; Michael A; Hall M; Goh JC; Lisyanskaya AS; DeSilvio M; Frangou E; Stronach EA; Gopalakrishna P; Meniawy TM; Gabra H
    Clin Cancer Res; 2019 Mar; 25(5):1472-1478. PubMed ID: 30563934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer.
    Ngoi NY; Syn NL; Goh RM; Goh BC; Huang RY; Soon YY; James E; Cook A; Clamp A; Tan DS
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD012007. PubMed ID: 35188221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
    Westin SN; Fu S; Tsimberidou A; Piha-Paul S; Akhmedzhanov F; Yilmaz B; McQuinn L; Brink AL; Gong J; Leung CH; Lin H; Hong DS; Pant S; Carter B; Jazaeri A; Gershenson D; Sood AK; Coleman RL; Shah J; Meric-Bernstam F; Naing A
    Gynecol Oncol; 2023 Jan; 168():76-82. PubMed ID: 36423446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.